EPHB4 and neoplasm: Pembrolizumab inhibits negative immune checkpoint signals, whereas EphB4-HSA is expected to decrease angiogenesis and cell growth of Efnb2 and/or EphB4 overexpressing tumor cells, while the albumin moiety will avoid renal clearance of the fusion protein, increasing its half-life without affecting immunogenicity.